

1. Collins AJ, Li S, Ma JZ, *et al.* Cardiovascular disease in end-stage renal disease patients. *Am J Kidney Dis* 2001;**38**:S26–S29.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;**32**:S112–S119.
3. Painter PL, Hector L, Ray K, *et al.* Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. *Am J Kidney Dis* 2003;**42**:362–9.
4. DePaul V, Moreland J, Eager T, *et al.* The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. *Am J Kidney Dis* 2002;**40**:1219–29.
5. Laukkanen JA, Kurl S, Salonen JT. Cardiorespiratory fitness and physical activity as risk predictors of future atherosclerotic cardiovascular diseases. *Curr Atheroscler Rep* 2002;**4**:468–76.
6. Prichard S. Risk factors for coronary artery disease in patients with renal failure. *Am J Med Sci* 2003;**325**:209–13.
7. Anonymous. Changes in ATP III focus on diabetes and the metabolic syndrome. *Am J Manag Care* 2002;(Suppl Symposium Reporter):1, 6.
8. Avram MM, Fein PA, Antignani A, *et al.* Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. *Am J Med* 1989;**87**:55N–60N.
9. Bachmann J, Tepel M, Raidt H, *et al.* Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. *J Am Soc Nephrol* 1995;**6**:121–5.

10. Bostom AG, Shemin D, Verhoef P, *et al.* Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. *Arterioscler Thromb Vasc Biol* 1997;**17**:2554–8.
11. Abdel-Raheem MM, Hebert B, Potti A, *et al.* Hyperhomocysteinemia and the risk of thromboembolic phenomenon in patients with chronic renal failure. *Thromb Res* 2002;**105**:299–302.
12. Bostom AG, Shemin D, Lapane KL, *et al.* High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. *Kidney Int* 1996;**49**:147–52.
13. Wilcken DE, Dudman NP, Tyrrell PA, *et al.* Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. *Metabolism* 1988;**37**:697–701.
14. Bostom AG, Shemin D, Yoburn D, *et al.* Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. *Atherosclerosis* 1996;**120**:241–4.
15. Kronenberg F, Neyer U, Lhotta K, *et al.* The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. *J Am Soc Nephrol* 1999;**10**:1027–36.
16. Black IW, Wilcken DE. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. *Clin Chem* 1992;**38**:353–7.
17. Nakahama H, Nakanishi T, Uyama O, *et al.* Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. *Ren Fail* 1993;**15**:189–93.

18. Becker BN, Himmelfarb J, Henrich WL, *et al.* Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. *J Am Soc Nephrol* 1997;**8**:475–86.
19. Panichi V, De Pietro S, Andreini B, *et al.* Cytokine production in haemodiafiltration: a multicentre study. *Nephrol Dial Transplant* 1998;**13**:1737–44.
20. Westhuyzen J, Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. *Ann Clin Lab Sci* 2000;**30**:133–43.
21. Viener A, Aviram M, Better OS, *et al.* Enhanced in vitro platelet aggregation in hemodialysis patients. *Nephron* 1986;**43**:139–43.
22. Sabo RS, Bartoli F, Apitz-Castro R. In vivo platelet hyperreactivity, another risk factor for patients under continuous ambulatory peritoneal dialysis. *Nephron* 1988;**49**:228–30.
23. Rubenstein MH, Sheynberg BV, Harrell LC, *et al.* Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure. *Am J Cardiol* 2001;**87**:856–60.
24. Nakayama Y, Sakata R, Ura M, *et al.* Long-term results of coronary artery bypass grafting in patients with renal insufficiency. *Ann Thorac Surg* 2003;**75**:496–500.